Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.97 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.97 |
| ▸ | PRCP | P42785 | 6/20 | 0.56 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.54 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.51 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2303831 | 1.00 | TSHR (0.97) | TSHRNPSR1PRCPSLC6A2SLC6A4 | |
| SCHEMBL29381539 | 1.00 | TSHR (0.97) | TSHRNPSR1PRCPSLC6A2SLC6A4 | |
| SCHEMBL29505877 | 1.00 | TSHR (0.97) | TSHRNPSR1PRCPSLC6A2SLC6A4 | |
| SCHEMBL29597389 | 1.00 | TSHR (0.97) | TSHRNPSR1PRCPSLC6A2SLC6A4 | |
| SCHEMBL574702 | 1.00 | TSHR (0.97) | TSHRNPSR1PRCPSLC6A2SLC6A4 | |
| Ammonia Solution, Strong SCHEMBL18066416 | 0.98 | TSHR (0.93) | TSHRNPSR1PRCPSLC6A2SLC6A4 | |
| Potassium SCHEMBL18066432 | 0.98 | TSHR (0.93) | TSHRNPSR1PRCPSLC6A2SLC6A4 | |
| SCHEMBL18066413 | 0.98 | TSHR (0.93) | TSHRNPSR1PRCPSLC6A2SLC6A4 | |
| Hydrochloric Acid SCHEMBL5439604 | 0.98 | TSHR (1.00) | TSHRNPSR1PRCPSLC6A2SLC6A4 | |
| Potassium SCHEMBL18066428 | 0.98 | TSHR (0.93) | TSHRNPSR1PRCPSLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1746 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240360177-A1 | PEPTIDES WITH ANTIMICROBIAL ACTIVITIES | AIMMAX THERAPEUTICS, INC. | 2024-10-31 | — | — | US | claimed |
| EP-4396196-A1 | PEPTIDES WITH ANTIMICROBIAL ACTIVITIES | Aimmax Therapeutics, Inc. (US) | 2024-07-10 | — | — | EP | claimed |
| CN-117897394-A | Peptides with antimicrobial activity | 美商安满药物开发公司 | 2024-04-16 | — | — | CN | claimed |
| EP-3145943-B1 | PEPTIDES, COMPOSITIONS COMPRISING THEM AND USES IN PARTICULAR COSMETIC USES | SEDERMA SA (FR) | 2024-03-13 | — | — | EP | claimed |
| WO-2023034481-A1 | PEPTIDES WITH ANTIMICROBIAL ACTIVITIES | AIMMAX THERAPEUTICS, INC. (US) | 2023-03-09 | — | — | WO | claimed |
| EP-2922864-B1 | PRO-PIGMENTING PEPTIDES | SEDERMA SA (FR) | 2023-01-04 | — | — | EP | claimed |
| CN-114364658-A | Preparation method and composition of levo-praziquantel and chiral intermediate thereof | 苏州同力生物医药有限公司 | 2022-04-15 | — | — | CN | claimed |
| WO-2021047565-A1 | METHOD FOR PREPARING (R)-PRAZIQUANTEL AND CHIRAL INTERMEDIATE THEREOF, AND COMPOSITION | 苏州同力生物医药有限公司 | 2021-03-18 | — | — | WO | claimed |
| CN-112480001-A | Method and composition for preparing levo-praziquantel chiral intermediate | 苏州同力生物医药有限公司 | 2021-03-12 | — | — | CN | claimed |
| US-20170137468-A1 | MODULATION OF COMPLEMENT ACTIVITY | UCB HOLDINGS, INC. | 2017-05-18 | — | — | US | claimed |
| JP-H08503694-A | — | — | 1996-04-23 | — | — | JP | claimed |
| EP-0664711-A1 | PEPTIDE INHIBITORS OF CELLULAR ADHESION | CENTOCOR INC. (US) | 1995-08-02 | — | — | EP | claimed |
| EP-0656904-A1 | PEPTIDE INHIBITORS OF SELECTIN BINDING | CENTOCOR INC. (US) | 1995-06-14 | — | — | EP | claimed |
| WO-1995014787-A1 | PEPTIDE INHIBITORS OF SELECTING BINDING | CENTOCOR, INC. (US) | 1995-06-01 | — | — | WO | claimed |
| WO-1995011921-A1 | BIVALENT THROMBIN INHIBITORS | NATIONAL RESEARCH COUNCIL OF CANADA (CA) | 1995-05-04 | — | — | WO | claimed |
| WO-1994005310-A1 | PEPTIDE INHIBITORS OF CELLULAR ADHESION | CENTOCOR, INC. (US) | 1994-03-17 | — | — | WO | claimed |
| EP-0584244-A1 | PEPTIDE INHIBITORS OF INFLAMMATION | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA (US) | 1994-03-02 | — | — | EP | claimed |
| WO-1993024526-A1 | PEPTIDE INHIBITORS OF SELECTIN BINDING | CENTOCOR, INC. (US) | 1993-12-09 | — | — | WO | claimed |
| WO-1993012091-A1 | D- AND L-1,2,3,4-TETRAHYDRO-ISOQUINOLINE-1-CARBOXYLIC ACIDS AND THEIR DERIVATIVES CONTAINING URETHANE-TYPE N-PROTECTING GROUPS AS WELL AS A PROCESS FOR PREPARING THEM AND THE CORRESPONDING RACEMATES | Gyógyszerkutató Intézet Kft. (HU) | 1993-06-24 | — | — | WO | claimed |
| WO-1992020708-A1 | PEPTIDE INHIBITORS OF INFLAMMATION | BOARD OF REGENTS FOR THE UNIVERSITY OF OKLAHOMA (US) | 1992-11-26 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170137468-A1 | MODULATION OF COMPLEMENT ACTIVITY | C5, C3AR1, CFH | TSHR 1539/4885NPSR1 1589/4885PRCP 157/4885 |
| US-20240360177-A1 | PEPTIDES WITH ANTIMICROBIAL ACTIVITIES | VIP, FPR2, FPR1 | TSHR 3292/4885NPSR1 616/4885PRCP 242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.